Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma

Tumor Biology

Volumn 36, Issue 8, 2015, Pages 5791-5799

  Fu, Hangcheng ^a   Liu, Yidong ^a   Xu, Le ^a   Liu, Weisi ^a   Fu, Qiang ^a   Liu, Haiou ^a   Zhang, Weijuan ^a,b   Xu, Jiejie ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Clear cell renal cell carcinoma; Galectin 9; Overall survival; Prognostic biomarker; Recurrence free survival

Indexed keywords

ECALECTIN; GALECTIN; LGALS9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TUMOR NECROSIS; TUMOR VOLUME; BIOSYNTHESIS; CARCINOMA, RENAL CELL; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE PERIOD; PROGNOSIS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; GALECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; POSTOPERATIVE PERIOD; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84940437799     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3248-y     Document Type: Article

References (26)

1. de Vivar Chevez AR, Finke J, Bukowski R. The role of inflammation in kidney cancer. Adv Exp Med Biol. 2014;816:197–234.
2. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, et al. Renal cell carcinoma guideline. Eur Urol. 2007;51:1502–10.
3. Itsumi M, Tatsugami K. Immunotherapy for renal cell carcinoma. Clin Dev Immunol. 2010;2010:284581.
4. Iliopoulos O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:5593–600.
5. Juengel E, Makarevic J, Reiter M, Mani J, Tsaur I, Bartsch G, et al. Resistance to the mtor inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin alpha5- and integrin beta3-dependent mechanism. Neoplasia. 2014;16:291–300.
6. Croci DO, Cerliani JP, Dalotto-Moreno T, Mendez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014;156:744–58.
7. Thijssen VL, Griffioen AW. Galectin-1 and -9 in angiogenesis: a sweet couple. Glycobiology. 2014.
8. Heusschen R, Schulkens IA, van Beijnum J, Griffioen AW, Thijssen VL. Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. Biochim Biophys Acta. 1842;2014:284–92.
9. Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, Yoshida N, et al. Galectin-9 induces apoptosis through the calcium–calpain–caspase-1 pathway. J Immunol. 2003;170:3631–6.
10. Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, Takeshita K, et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology. 2008;18:735–44.
11. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245–52.
12. Fujihara S, Mori H, Kobara H, Rafiq K, Niki T, Hirashima M, et al. Galectin-9 in cancer therapy. Recent Patents Endocr Metab Immune Drug Discov. 2013;7:130–7.
13. Heusschen R, Griffioen AW, Thijssen VL. Galectin-9 in tumor biology: a jack of multiple trades. Biochim Biophys Acta. 2013;1836:177–85.
14. Yuan J, Jiang B, Zhao H, Huang Q. Prognostic implication of Tim-3 in clear cell renal cell carcinoma. Neoplasma. 2014;61:35–40.
15. Xu J, Yun X, Jiang J, Wei Y, Wu Y, Zhang W, et al. Hepatitis B virus X protein blunts senescence like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology. 2010;52:142–54.
16. Wada J, Kanwar YS. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem. 1997;272:6078–86.
17. Wiersma VR, de Bruyn M, Helfrich W, Bremer E. Therapeutic potential of galectin-9 in human disease. Med Res Rev. 2013;33 Suppl 1:E102–126.
18. Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis b virus-associated hepatocellular carcinoma. Hepatology. 2012;56:1342–51.
19. Zhu C, Anderson AC, Kuchroo VK. Tim-3 and its regulatory role in immune responses. Curr Top Microbiol Immunol. 2011;350:1–15.
20. Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11:2962–8.
21. Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, et al. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer J Int Cancer. 2002;99:809–16.
22. Liang M, Ueno M, Oomizu S, Arikawa T, Shinonaga R, Zhang S, et al. Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J Cancer Res Clin Oncol. 2008;134:899–907.
23. Zhang ZY, Dong JH, Chen YW, Wang XQ, Li CH, Wang J, et al. Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pacific J Cancer Prev: APJCP. 2012;13:2503–9.
24. 24 Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners. 2014.
25. Leitner J, Rieger A, Pickl WF, Zlabinger G, Grabmeier-Pfistershammer K, Steinberger P. Tim-3 does not act as a receptor for galectin-9. PLoS Pathog. 2013;9:e1003253.
26. Kawashima H, Obayashi A, Kawamura M, Masaki S, Tamada S, Iguchi T, et al. Galectin 9 and pinch, novel immunotherapy targets of renal cell carcinoma: a rationale to find potential tumour antigens and the resulting cytotoxic T lymphocytes induced by the derived peptides. BJU Int. 2014;113:320–32.